Thrive: What’s the first thing you do when you get out of bed? Lisa Jewell: Check my phone. I go to my email first, and
Category: Medical Devices
US Secretary of State Blinken to visit Africa as tension with China and Russia intensifies
By Landry Signé Secretary of State Antony Blinken and his team will be in sub-Saharan Africa from August 7 to 12, paying visits to three
US Secretary of State Blinken to visit Africa as tension with China and Russia intensifies
By Landry Signé Secretary of State Antony Blinken and his team will be in sub-Saharan Africa from August 7 to 12, paying visits to three
What Ayman al-Zawahri’s death says about terrorism in Taliban-run Afghanistan
By Vanda Felbab-Brown The successful U.S. hit against Ayman al-Zawahri, the post-Osama bin Laden leader of al-Qaida, is a great moment of justice: Zawahri had
Corporate Good vs. Social Good: Can Investors Have Both?
In an episode of the “All Else Equal” podcast series from Stanford Graduate School of Business, Wharton’s Jules van Binsbergen and Stanford’s Jonathan Berk discuss
How sharp will be the global slowdown?
By Justin Damien Guénette The Russian Federation’s invasion of Ukraine was yet another supply shock to a global economy still reeling from the consequences of
How sharp will be the global slowdown?
By Justin Damien Guénette The Russian Federation’s invasion of Ukraine was yet another supply shock to a global economy still reeling from the consequences of
Succeeding with Hybrid Work: Focus on Five Cs
If you’re struggling to manage a hybrid team or workforce, start by understanding five key challenges, says Wharton’s Martine Haas in this Nano Tool for
Is the Fed Going Too Far Beyond Its Mandate?
The Minneapolis Federal Reserve’s moves to shape state education policy have triggered a broader debate on central bank activism. Wharton’s Christina Parajon Skinner weighs in.…Read More
STAT+: With new data on its KRAS-blocking lung cancer drug, Mirati expects to take on a rival Amgen treatment
As Mirati Therapeutics waits for the Food and Drug Administration to complete a review of its KRAS-targeting lung cancer drug later this year, final results